Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:GEMP

Gemphire Therapeutics (GEMP) Stock Price, News & Analysis

Gemphire Therapeutics logo

About Gemphire Therapeutics Stock (NASDAQ:GEMP)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$1.52
$1.61
50-Day Range
$0.30
$6.38
52-Week Range
$0.24
$1.49
Volume
8,832 shs
Average Volume
127,174 shs
Market Capitalization
$22.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.

Remove Ads
Receive GEMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gemphire Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GEMP Stock News Headlines

Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Musk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to help build human colonies on the Red Planet. And here on Earth? Optimus is about to change everything.
See More Headlines

GEMP Stock Analysis - Frequently Asked Questions

Gemphire Therapeutics Inc (NASDAQ:GEMP) issued its quarterly earnings results on Friday, March, 15th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.15.

Gemphire Therapeutics (GEMP) raised $30 million in an IPO on Friday, August 5th 2016. The company issued 3,000,000 shares at $10.00 per share. Jefferies and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gemphire Therapeutics investors own include TG Therapeutics (TGTX), AcelRx Pharmaceuticals (ACRX), Pixelworks (PXLW), Clearside Biomedical (CLSD), Protalix BioTherapeutics (PLX), SCYNEXIS (SCYX) and Melinta Therapeutics (MLNT).

Company Calendar

Last Earnings
3/15/2019
Today
4/01/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GEMP
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-23,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.54 per share
Price / Book
2.85

Miscellaneous

Free Float
N/A
Market Cap
$22.90 million
Optionable
Not Optionable
Beta
2.82
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:GEMP) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners